CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 84 filers reported holding CRISPR THERAPEUTICS AG in Q4 2017. The put-call ratio across all filers is 0.44 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $39,622,337 | -23.4% | 872,931 | -5.3% | 0.04% | -21.6% |
Q2 2023 | $51,741,768 | +35.0% | 921,656 | +8.8% | 0.05% | +30.8% |
Q1 2023 | $38,322,158 | +10.5% | 847,273 | -0.7% | 0.04% | +5.4% |
Q4 2022 | $34,669,939 | -36.9% | 852,889 | +1.4% | 0.04% | -39.3% |
Q3 2022 | $54,940,000 | -2.1% | 840,706 | -9.0% | 0.06% | +5.2% |
Q2 2022 | $56,131,000 | -12.1% | 923,671 | -9.3% | 0.06% | +5.5% |
Q1 2022 | $63,888,000 | -26.2% | 1,017,827 | -10.9% | 0.06% | +19.6% |
Q4 2021 | $86,590,000 | -23.5% | 1,142,652 | +13.0% | 0.05% | -25.8% |
Q3 2021 | $113,189,000 | -34.2% | 1,011,241 | -4.8% | 0.06% | -31.9% |
Q2 2021 | $171,930,000 | +34.0% | 1,062,014 | +0.9% | 0.09% | +40.0% |
Q1 2021 | $128,310,000 | +1.8% | 1,053,010 | +28.0% | 0.06% | +6.6% |
Q4 2020 | $126,001,000 | +111.3% | 822,944 | +15.4% | 0.06% | +69.4% |
Q3 2020 | $59,642,000 | +11.8% | 713,086 | -1.8% | 0.04% | -5.3% |
Q2 2020 | $53,347,000 | +47.7% | 725,910 | -14.8% | 0.04% | +22.6% |
Q1 2020 | $36,127,000 | -17.8% | 851,867 | +18.1% | 0.03% | -3.1% |
Q4 2019 | $43,931,000 | +46.8% | 721,312 | -1.2% | 0.03% | +28.0% |
Q3 2019 | $29,916,000 | -20.5% | 729,828 | -8.6% | 0.02% | -24.2% |
Q2 2019 | $37,608,000 | +18.2% | 798,472 | -10.3% | 0.03% | +13.8% |
Q1 2019 | $31,810,000 | +43.7% | 890,564 | +14.9% | 0.03% | +26.1% |
Q4 2018 | $22,138,000 | -16.3% | 774,873 | +30.0% | 0.02% | -4.2% |
Q3 2018 | $26,435,000 | +17.8% | 596,052 | +56.0% | 0.02% | +9.1% |
Q2 2018 | $22,450,000 | +9.9% | 382,064 | -14.5% | 0.02% | +15.8% |
Q1 2018 | $20,435,000 | +96.5% | 447,048 | +0.9% | 0.02% | +111.1% |
Q4 2017 | $10,398,000 | +626.6% | 442,845 | +453.2% | 0.01% | +800.0% |
Q3 2017 | $1,431,000 | +11.6% | 80,048 | +0.1% | 0.00% | 0.0% |
Q2 2017 | $1,282,000 | -26.4% | 80,000 | 0.0% | 0.00% | -50.0% |
Q1 2017 | $1,742,000 | – | 80,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |